NCT00791167View on ClinicalTrials.gov

A Study of the Dose Proportionality of Extended Release Paliperidone

PHASE1CompletedINTERVENTIONAL

Enrollment

58

Participants

Timeline

Start Date

June 30, 2006

Study Completion Date

August 31, 2006

Conditions

Schizophrenia

Interventions

DRUG

Paliperidone ER

All Listed Sponsors

lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00791167 - A Study of the Dose Proportionality of Extended Release Paliperidone | Biotech Hunter | Biotech Hunter